medigraphic.com

2018, Number 1

<< Back Next >>

Rev Clin Esc Med 2018; 8 (1)

Terapia génica en el arsenal de terapéutica de la enfermedad oncológica

Morales GF

Language: Spanish
References: 25
Page: 11-17
PDF size: 220.25 Kb.


ABSTRACT

Gene therapy is an intervention modality that although it was initially proposed for the modification of metabolic diseases with exogen modification only as the research progresses, it presents an incredible range of potential mechanisms of action and therapeutic targets mainly in the management of the oncological disease.


REFERENCES

  1. Giacca M. Gene Therapy [Internet]. Milano: Springer Milan; 2010 [citado 21 de noviembre de 2017]. Disponible en: http://link.springer.com/10.1007/978- 88-470-1643-9

  2. Friedmann T. A brief history of gene therapy. Nat Genet. octubre de 1992;2(2):93–8.

  3. Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet. mayo de 2015;52(5):289–96.

  4. Li B, Gao N, Zhang Z, Chen Q, Li L, Li Y. Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China. Genes. 24 de febrero de 2017;8(3):85.

  5. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update: Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. febrero de 2013;15(2):65–77.

  6. Husain SR, Han J, Au P, Shannon K, Puri RK. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther. diciembre de 2015;22(12):554–63.

  7. Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. agosto de 2013;525(2):162–9.

  8. Adriaansen J, Vervoordeldonk MJBM, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology. 1 de junio de 2006;45(6):656–68.

  9. Naldini L. Gene therapy returns to centre stage. Nature. 14 de octubre de 2015;526(7573):351–60.

  10. Ma H, Marti-Gutierrez N, Park S-W, Wu J, Lee Y, Suzuki K, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2 de agosto de 2017;548(7668):413–9.

  11. Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, et al. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Science. 14 de marzo de 2014;343(6176):1247997–1247997.

  12. Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 18 de enero de 2017;541(7637):321–30.

  13. Chen Y, Gao D-Y, Huang L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv Drug Deliv Rev. enero de 2015;81:128–41.

  14. Annan AC, Fisher PB, Dent P, Siegal GP, Curiel DT. Gene Therapy in the Treatment of Human Cancer. En: Coleman WB, Tsongalis GJ, editores. The Molecular Basis of Human Cancer [Internet]. New York, NY: Springer New York; 2017 [citado 16 de noviembre de 2017]. p. 811–41. Disponible en: http://link.springer.com/10.1007/978-1- 59745-458-2_42

  15. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive Immunotherapy for Cancer or Viruses. Annu Rev Immunol. 21 de marzo de 2014;32(1):189–225.

  16. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy- Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. J Clin Oncol. 20 de febrero de 2015;33(6):540–9.

  17. Portnow J, Synold TW, Badie B, Tirughana R, Lacey SF, D’Apuzzo M, et al. Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. Clin Cancer Res. 15 de junio de 2017;23(12):2951–60.

  18. Almåsbak H, Aarvak T, Vemuri MC. CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res. 2016;2016:1–10.

  19. Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy. julio de 2015;7(6):611– 9.

  20. Peng Z. Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers. Hum Gene Ther. septiembre de 2005;16(9):1016–27.

  21. Sakhawat A, Liu Y, Ma L, Muhammad T, Wang S, Zhang L, et al. Upregulation of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung Cancer Cells to CRAd-Induced Inhibition. J Cancer. 2017;8(8):1425–32.

  22. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis. abril de 2009;14(4):597– 606.

  23. Wirth T, Samaranayake H, Pikkarainen J, Määttä A-M, Ylä-Herttuala S. Clinical trials for glioblastoma multiforme using adenoviral vectors. Curr Opin Mol Ther. octubre de 2009;11(5):485–92.

  24. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 21 de febrero de 1990;82(4):297–300.

  25. Konieczny P, Sułkowski M, Badyra B, Kijowski J, Majka M. Suicide gene therapy of rhabdomyosarcoma. Int J Oncol. febrero de 2017;50(2):597–605.




2020     |     www.medigraphic.com